ELVN-001 Chronic Myeloid Leukemia CML
"ELVN-001 was also designed to be active against the T315I mutation, the most common BCR-ABL mutation, which confers resistance to nearly all approved TKIs. Importantly, ELVN-001 was designed to be a more attractive option for patients with comorbidities, on concomitant medications or desiring more freedom from stringent administration requirements."
Extract of Enliven Therapeutics
